Creative Planning
MYGN icon

Creative Planning’s Myriad Genetics MYGN Stock Holding History

Creative Planning’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,000
Closed -$5K – 4281
2014
Q3 		$5K Hold
2,000
– – ﹤0.01% 3300
2014
Q2 		$9K Buy
+2,000
New +$74.4K ﹤0.01% 2934

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Creative Planning's MYGN Position: Q1 2026 in Review

Creative Planning reduced its Myriad Genetics (MYGN) stake by 4.7% in Q1 2026, selling an estimated $18.2K and leaving 70,241 shares worth $316K. The position accounts for ﹤0.01% of the portfolio, ranked #3386.

Creative Planning first reported a position in MYGN in Q2 2013 and has held it in 31 quarters since. The position peaked at $562K in Q3 2025. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Creative Planning held 70,241 shares of Myriad Genetics worth $316K as of Q1 2026.
  • Creative Planning sold 3,497 Myriad Genetics shares in Q1 2026, an estimated $18.2K.
  • Myriad Genetics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3386 holding.
  • Creative Planning first reported a position in Myriad Genetics in Q2 2013 and has held it in 31 quarters since.
  • Creative Planning's Myriad Genetics position peaked at $562K in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.